Published in S Afr Med J on January 01, 2004
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Seven years of regional malaria control collaboration--Mozambique, South Africa, and Swaziland. Am J Trop Med Hyg (2007) 6.04
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med (2009) 3.38
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother (2006) 2.35
The World Bank: false financial and statistical accounts and medical malpractice in malaria treatment. Lancet (2006) 2.22
In vitro antiplasmodial activity of medicinal plants native to or naturalised in South Africa. J Ethnopharmacol (2004) 2.11
Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa. Trop Med Int Health (2004) 1.89
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? Malar J (2008) 1.77
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J (2007) 1.56
Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol (2007) 1.49
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol (2008) 1.39
A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol (2007) 1.37
Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother (2005) 1.35
The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malar J (2007) 1.25
The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol (2006) 1.17
Antimalarial treatment with artemisinin combination therapy in Africa. BMJ (2005) 1.15
Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. Drug Saf (2007) 1.11
Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). Malar J (2010) 1.11
Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS One (2011) 1.04
Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. Am J Trop Med Hyg (2008) 1.03
Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg (2010) 1.03
Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J (2014) 1.01
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (2005) 0.98
How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials. BMC Med Res Methodol (2013) 0.90
Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int (2007) 0.89
Establishing pharmacovigilance programs in resource-limited settings: the example of treating malaria. Expert Rev Clin Pharmacol (2010) 0.88
Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. Tuberculosis (Edinb) (2007) 0.86
Evaluation of selected South African ethnomedicinal plants as mosquito repellents against the Anopheles arabiensis mosquito in a rodent model. Malar J (2010) 0.86
Exploring the seasonality of reported treated malaria cases in Mpumalanga, South Africa. PLoS One (2013) 0.85
Towards malaria elimination in Mpumalanga, South Africa: a population-level mathematical modelling approach. Malar J (2014) 0.83
Screening of selected ethnomedicinal plants from South Africa for larvicidal activity against the mosquito Anopheles arabiensis. Malar J (2012) 0.82
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol (2012) 0.80
Nonlinear mixed effects modeling of gametocyte carriage in patients with uncomplicated malaria. Malar J (2010) 0.79
Screening for adulticidal bioactivity of South African plants against Anopheles arabiensis. Malar J (2011) 0.78
Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. Malar J (2011) 0.76
Comment on: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg (2005) 0.75
Rolling back malaria in Africa. S Afr Med J (2007) 0.75